AB Science

AB Science sits in the biotech space, where companies are judged less by branding than by the science they can turn into medicines. By our assessment, that makes it interesting for people who follow drug development, because the whole category lives or dies on research, trials, and regulatory progress. The downside is the usual biotech one: a company can have a compelling story and still remain far from a finished treatment, so patience matters more than polish. In practice, this kind of firm is about labs, pipelines, and waiting for evidence, not about a neat consumer product you can size up in one glance. Against larger pharmaceutical groups, AB Science feels more focused and more dependent on a small number of programmes. It is for readers who care about experimental medicine and can live with uncertainty, and not for anyone wanting a simple, predictable business story.